Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lactate Dehydrogenase-5 and Tumor-Infiltrating Lymphocytes in Prostate Cancer Patients Undergoing Radical Hypofractionated Radiotherapy.

Cancers·2026

Same author

Protocol for the NEURO-BREAC-02 Trial: Evaluation of a Self-Assessment Tool for Mild Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors.

Journal of clinical medicine·2026

Same author

HBV pgRNA induces chronic inflammation in an IL-1β-dependent manner.

Frontiers in immunology·2026

Same author

Life-Threatening Gastrointestinal Bleeding Revealing a Rare Coexistence of Ampullary Ganglioneuroma and Pancreatic Neuroendocrine Tumor: A Case Report.

Diagnostics (Basel, Switzerland)·2026

Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026

Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

ARID1 and BRG1 Expression in Endometrial Cancer.

Emmanuel N Kontomanolis¹, Panagiotis Symeonidis², Konstantinos Nikolettos²

¹Department of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece; mek-2@otenet.gr.

In Vivo (Athens, Greece)

|April 30, 2024

Summary

Loss of ARID1A expression in endometrial cancer may serve as a biomarker for guiding treatment. Further research is needed, particularly for early-stage disease, to confirm its prognostic value.

Keywords:

ARID1A BRG1 Endometrial cancer SWI/SNF biomarkers

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Related Experiment Videos

Last Updated: Jun 27, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Area of Science:

Oncology
Gynecologic Oncology
Molecular Pathology

Background:

Endometrial cancer (EC) is a prevalent gynecologic malignancy.
SWI/SNF complex subunits, including ARID1A and BRG1, are implicated in EC development.
Novel prognostic biomarkers for EC are actively sought.

Purpose of the Study:

To investigate the expression patterns of ARID1A and BRG1 in endometrioid endometrial cancer.
To assess the correlation of ARID1A and BRG1 expression with clinicopathological features of EC.

Main Methods:

Immunohistochemistry was used to evaluate ARID1A and BRG1 expression in 33 stage I endometrioid EC patients.
Cytoplasmic and nuclear protein expression was assessed.
Expression levels were correlated with tumor grade and myometrial invasion.

Main Results:

ARID1A showed both nuclear and cytoplasmic expression, with decreased levels in grade 3 tumors and association with endocervical expansion.
A significant reduction or absence of ARID1A expression was observed in 78% of cases.
BRG1 was predominantly nuclear and rarely down-regulated, precluding statistical analysis.

Conclusions:

ARID1A expression loss is a potential biomarker for guiding adjuvant therapy in endometrial cancer.
Further studies are warranted to validate ARID1A as a prognostic marker, especially in early-stage EC.